Using Cabozantinib + Nivolumab to Treat Advanced Renal Cell Carcinoma

Video

A discussion on the use of cabozantinib-nivolumab for the treatment of advanced renal cell carcinoma.

Arnab Basu, MD: Could you explain your decision-making process in choosing cabozantinib-nivolumab for this patient?

Shawnta Anakwah, MD: This patient was older. He didn’t have a lot of bulky disease, just the nonspecific mediastinal lymphadenopathy. This guy has psoriasis, so that would be a concern with choosing dual I/O [immune-oncology] therapy with him flaring up. The decision was made to do cabozantinib-nivolumab on him.

Arnab Basu, MD: That makes a lot of sense. Thank you. When you use cabozantinib-nivolumab in your practice, are there common adverse events that occur more frequently with this regimen?

Shawnta Anakwah, MD: Blood pressure—hypertension is definitely a common 1. I’ve seen some diarrhea as well as stomatitis. I’ve just treated symptom based. With those interruptions first, I treat symptom based, and all my patients have done very well. I’ve been able to continue treatment.

Dr Basu, what’s been your experience with the cabozantinib-nivolumab combination in your practice?

Arnab Basu, MD: I’ve had a good experience with cabozantinib-nivolumab. It’s a very well tolerated regimen. There are published data for cabozantinib-nivolumab compared with sunitinib in terms of FKSI-17 [Functional Assessment of Cancer Therapy–Kidney Symptom Index] quality-of -life measures, and cabozantinib-nivolumab performs very differently in those. The fact that we start with a 40-mg dose of cabozantinib is really good—it’s a sweet spot for a cabozantinib dose in most patients. I’ve found it to be well tolerated to start with. But I agree, the issues that occur tend to be hypertension, occasional diarrhea, and some upper–GI [gastrointestinal] adverse effects, as well with a lot of GERD [gastroesophageal reflux disease] and GI irritation adverse effects. Otherwise, patients tolerated well at the 40-mg dosing.

Transcript edited for clarity.

Related Videos
Samer A. Srour, MB ChB, MS
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Wenxin (Vincent) Xu, MD,
Related Content
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Professor Jun Guo, MD, PhD, from Peking University Cancer Hospital

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

April 9th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
Shankar Siva, PhD, MBBS, FRANZCR, Peter MacCallum Cancer Centre

SABR Leads to Local Control in Primary RCC Without Surgery

April 3rd 2024
Article
John McGrane, MD, consultant oncologist, Royal Cornwall Hospitals NHS Trust

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024
Article